Our results demonstrate that C021, a class-I CCR4 antagonist, exerts multiple antitumor effects on CTCL cells in vitro and inhibits tumor growth in CTCL xenograft mice in vivo, whereas AZD-2098, a class-II CCR4 antagonist, does not show the same efficacy. Here, CCR4 is linked to neoplasm.